Lucid Diagnostics (NASDAQ:LUCD – Get Free Report) and Treace Medical Concepts (NASDAQ:TMCI – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, valuation, dividends, risk and earnings.
Risk & Volatility
Lucid Diagnostics has a beta of 1.1, indicating that its stock price is 10% more volatile than the S&P 500. Comparatively, Treace Medical Concepts has a beta of 1.1, indicating that its stock price is 10% more volatile than the S&P 500.
Valuation and Earnings
This table compares Lucid Diagnostics and Treace Medical Concepts”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Lucid Diagnostics | $4.71 million | 45.19 | -$58.01 million | ($0.96) | -1.14 |
| Treace Medical Concepts | $212.69 million | 0.57 | -$59.00 million | ($0.94) | -2.00 |
Lucid Diagnostics has higher earnings, but lower revenue than Treace Medical Concepts. Treace Medical Concepts is trading at a lower price-to-earnings ratio than Lucid Diagnostics, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of recent ratings and price targets for Lucid Diagnostics and Treace Medical Concepts, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Lucid Diagnostics | 1 | 0 | 4 | 0 | 2.60 |
| Treace Medical Concepts | 2 | 4 | 1 | 0 | 1.86 |
Lucid Diagnostics currently has a consensus price target of $4.13, indicating a potential upside of 278.44%. Treace Medical Concepts has a consensus price target of $4.77, indicating a potential upside of 153.72%. Given Lucid Diagnostics’ stronger consensus rating and higher probable upside, research analysts clearly believe Lucid Diagnostics is more favorable than Treace Medical Concepts.
Profitability
This table compares Lucid Diagnostics and Treace Medical Concepts’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Lucid Diagnostics | -1,426.27% | N/A | -95.51% |
| Treace Medical Concepts | -27.74% | -59.91% | -28.44% |
Insider & Institutional Ownership
74.0% of Lucid Diagnostics shares are owned by institutional investors. Comparatively, 84.1% of Treace Medical Concepts shares are owned by institutional investors. 6.8% of Lucid Diagnostics shares are owned by company insiders. Comparatively, 23.4% of Treace Medical Concepts shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Summary
Lucid Diagnostics beats Treace Medical Concepts on 7 of the 13 factors compared between the two stocks.
About Lucid Diagnostics
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.
About Treace Medical Concepts
Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty 3D bunion correction system that combines instruments, implants, and surgical methods designed to surgically correct three planes of the bunion deformity. It also provides Lapiplasty mini-incision system designed to allow the Lapiplasty procedure to be performed through a 3.5cm incision. In addition, the company offers Adductoplasty system designed for reproducible realignment, stabilization, and fusion of the midfoot. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra, Florida.
Receive News & Ratings for Lucid Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lucid Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
